ArticleEMBO reports2026
Combinatorial effects of multiple genes contribute to beneficial aneuploidy phenotypes.
Article in EMBO reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Aneuploidy is one of the most common adaptive mechanisms to environmental selection in cells, yet its advantages over other genomic alterations remain unclear. We used budding yeast to determine if beneficial aneuploidy phenotypes are driven primarily by combinatorial expression changes of multiple genes. To determine the impact of complex aneuploidy on cellular fitness and drug resistance, we generated yeast collections with nearly every combination of two chromosome gains or losses. Additionally, we genetically dissected aneuploid chromosomes using partial deletions to identify chromosomal regions contributing to aneuploidy-driven drug resistance. Strong resistance phenotypes consistently came from combinations of chromosomes or chromosomal regions, with up to five regions on a chromosome contributing to resistance to a single drug. Gene ontology terms had limited predictive power in identifying the genes contributing to resistance phenotypes, as the combinatorial effects from different aneuploid regions act through multiple resistance pathways. The strongest phenotypes came from synergistic effects between copy number changes of different chromosomes or chromosomal regions, demonstrating how subtle gene expression changes of many genes combine to greatly impact cell survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.